1
|
Djemal L, von Hagen J, Kolmar H, Deparis V. Characterization of soy protein hydrolysates and influence of its iron content on monoclonal antibody production by a murine hybridoma cell line. Biotechnol Prog 2021; 37:e3147. [PMID: 33742790 DOI: 10.1002/btpr.3147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/23/2021] [Accepted: 03/16/2021] [Indexed: 11/12/2022]
Abstract
A challenging aspect with the use of protein hydrolysates in commercial manufacturing processes of recombinant therapeutic proteins is their impacts on the protein production due to a lack of understanding of batch-to-batch variability. Soy hydrolysates variability and its impact on fed-batch production of a recombinant monoclonal antibody (mAb) expressed in Sp2/0 cells were studied using 37 batches from the same vendor. The batch-to-batch variability of soy hydrolysates impacted cell growth, titer and product quality. Physicochemical characterization of batches confirmed that soy hydrolysates are mainly a source of amino acids and peptides containing lower amounts of other components such as carbohydrates and chemical elements in cell culture media. Soy hydrolysates composition of different batches was consistent except for trace elements. Statistical analyses identified iron as a potential marker of a poor process performance. To verify this correlation, two forms of iron, ferric ammonium citrate and ferrous sulfate, were added to a batch of soy hydrolysates associated to a low level of iron during cell culture. Both forms of iron reduced significantly cell growth, mAb titer and increased level of the acidic charge variants of the mAb. Consequently, trace element composition of soy hydrolysates or of all incoming raw materials might lead to significant impacts on process performance and product quality and therefore need to be tightly controlled.
Collapse
Affiliation(s)
- Leïla Djemal
- Manufacturing Science and Technology, Heathcare, Merck KGaA, Corsier-sur-Vevey, Switzerland.,Department of Applied Biochemistry, Technical University of Darmstadt, Darmstadt, Germany
| | | | - Harald Kolmar
- Department of Applied Biochemistry, Technical University of Darmstadt, Darmstadt, Germany
| | - Véronique Deparis
- Manufacturing Science and Technology, Heathcare, Merck KGaA, Corsier-sur-Vevey, Switzerland
| |
Collapse
|
2
|
Miranda M, Cova T, Augusto C, Pais AACC, Cardoso C, Vitorino C. Diving into Batch-to- Batch Variability of Topical Products-a Regulatory Bottleneck. Pharm Res 2020; 37:218. [PMID: 33037479 DOI: 10.1007/s11095-020-02911-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Accepted: 08/17/2020] [Indexed: 12/18/2022]
Abstract
PURPOSE Following the recent European Medicine Agency (EMA) draft guideline on quality and equivalence of topical products, a modular framework for bioequivalence assessment is proposed, wherein the qualitative, quantitative, microstructure and product performance sameness is demanded to support generic applications. Strict regulatory limits are now imposed, but, the suitability of these limits has been subject of intense debate. In this context, this paper aims to address these issues by characterizing a panel of 8 reference blockbuster semisolid topical products. METHODS For each product, three batches were selected and, whenever possible, batches retrieved from different manufacturing sites were considered. Product microstructure was evaluated in terms of globule size, pH, rheological attributes and, if required, the thermal behaviour was also assessed. Performance was evaluated through in vitro release testing (IVRT). Finally, an integrated multivariate analysis was performed to highlight the features that most contribute for product variability. RESULTS Marked differences were registered within reference products. Statistical analysis demonstrated that if EMA criteria are applied, none of the same product batches can be considered as equivalent. Rheological parameters as well as IVRT indicators account for the majority of batch-to-batch differences. CONCLUSIONS Semisolid dosage forms exhibit intrinsic variability. This calls for the attention to the need of establishing reasonable equivalence criteria applied to generic drug products. Graphical abstract.
Collapse
Affiliation(s)
- Margarida Miranda
- Faculty of Pharmacy, University of Coimbra, Portugal, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal
- Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535, Coimbra, Portugal
| | - Tânia Cova
- Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535, Coimbra, Portugal
| | - Cátia Augusto
- Laboratórios Basi, Mortágua, Parque Industrial Manuel Lourenço Ferreira, Portugal, lote 15 3450-232, Mortágua, Portugal
| | - Alberto A C C Pais
- Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535, Coimbra, Portugal
| | - Catarina Cardoso
- Laboratórios Basi, Mortágua, Parque Industrial Manuel Lourenço Ferreira, Portugal, lote 15 3450-232, Mortágua, Portugal
| | - Carla Vitorino
- Faculty of Pharmacy, University of Coimbra, Portugal, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548, Coimbra, Portugal.
- Coimbra Chemistry Center, Department of Chemistry, University of Coimbra, Rua Larga, 3004-535, Coimbra, Portugal.
- Centre for Neurosciences and Cell Biology (CNC), Faculty of Medicine, University of Coimbra, Rua Larga, Pólo I, 1st floor, 3004-504, Coimbra, Portugal.
| |
Collapse
|